Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives

Fig. 1

Mechanisms of action of antibodies targeting T-ALL cell and CAR-T cell approach. Antibodies induce tumor cell-killing through different mechanisms: (1) initiating the complement cascade [complement-dependent cytotoxicity (CDC)]; (2) delivering cytotoxic drugs to be internalised in tumor cells [antibody–drug conjugation (ADC)]; (3) activating immune effector cells, namely NK cells [antibody-dependent cytotoxicity (ADCC)] or (4) macrophages [antibody-dependent cellular phagocytosis (ADCP)]. On the other hand, CAR-T cells act (5) recognizing and killing cancer cells through the release of inflammatory cytokines and cytolytic molecules

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us